Dr. Jasmohan Bajaj, MD
Claim this profileHunter Holmes McGuire VA Medical Center
Studies Liver Cirrhosis
Studies Fibrosis
7 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Jasmohan Bajaj, MD is currently running
Prebiotics
for PTSD and Liver Cirrhosis
Despite medical advancements, PTSD remains a major issue in Veterans1. Current treatment strategies have relatively poor adherence. In patients with PTSD and cirrhosis, there is greater cognitive impairment as well as changes in gut microbiome structure and function2,3. In addition, when there is concomitant cirrhosis, medication-related treatment options become even narrower from a safety and tolerability perspective and cognitive issues pertaining to cirrhosis could impact participation3. Changes in gut microbiome in Veterans with cirrhosis and PTSD compared to those with cirrhosis without PTSD is characterized by a greater relative expression of pathobionts and reduction in stool microbiome diversity with reduction in bacteria that produce beneficial short chain fatty acids (SCFA)2. Modulation of the gut microbiome in patients with cirrhosis and PTSD may be an important therapeutic target. In prior studies with cirrhosis alone, microbial modulation using diet, antibiotics such as rifaximin, probiotics, and fecal microbiota transplant have improved gut microbial diversity and clinical outcomes in some cases4,5. In patients with cirrhosis without PTSD and in patients with PTSD without cirrhosis there is emerging evidence regarding prebiotics and other forms of gut microbial modulation. Prebiotics are such an example6. Prebiotics are natural fibers derived from carbohydrates and can be beneficial to gut microbiota (good bacteria in the gut)6. Resistant starches (RS) are dietary fiber prebiotics found naturally in many foods including potatoes, plantains, and legumes6,7. In addition to being highly accessible, RS have been shown to be well tolerated with few adverse reactions. While no studies of RS exist in PTSD + cirrhosis patients, a meta-analysis of RS in IBD has shown RS to be an effective treatment in both animal and clinical studies where improvements in clinical remission and reduced mucosal damage were found7. However, there is insufficient data regarding patients with PTSD and cirrhosis regarding gut microbial structure and function modulation with dietary supplements such as resistant starches. These starches can improve SCFA production in elderly subjects, which could in turn affect the gut-brain axis favorably8.
Recruiting1 award N/A3 criteria
Plasma Exchange
for Liver Failure
This is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study centers in the United States, Canada, and Europe with expertise in the management of subjects with ACLF. Subjects with ACLF at a high risk of hospital mortality will be enrolled. The study will consist of a Screening Period during which subjects will be randomized (1:1) to receive either standard medical treatment (SMT) + PE-A 5% (treatment group) or SMT only (control group), followed by a Treatment Period, and a Follow-up Period. The Treatment Period for subjects in the SMT+ PE-A 5% treatment group will be between 7 and 17 days, depending on ACLF evolution. The Treatment Period for subjects in the SMT control group will be a minimum of 7 days for all subjects and up to 17 days depending on the ACLF evolution. Subjects in this group will receive SMT according to the institution's standards. The Follow-up Period for subjects in both groups will be 90 days.
Recruiting3 awards Phase 3
More about Jasmohan Bajaj, MD
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jasmohan Bajaj, MD has experience with
- Simvastatin
- Alfapump
- IV Albumin
- Placebo
- One Meal
- Albumin
Breakdown of trials Jasmohan Bajaj, MD has run
Liver Cirrhosis
Fibrosis
Brain Diseases
Encephalopathy
Ascites
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jasmohan Bajaj, MD specialize in?
Jasmohan Bajaj, MD focuses on Liver Cirrhosis and Fibrosis. In particular, much of their work with Liver Cirrhosis has involved treating patients, or patients who are undergoing treatment.
Is Jasmohan Bajaj, MD currently recruiting for clinical trials?
Yes, Jasmohan Bajaj, MD is currently recruiting for 3 clinical trials in Richmond Virginia. If you're interested in participating, you should apply.
Are there any treatments that Jasmohan Bajaj, MD has studied deeply?
Yes, Jasmohan Bajaj, MD has studied treatments such as Simvastatin, Alfapump, IV Albumin.
What is the best way to schedule an appointment with Jasmohan Bajaj, MD?
Apply for one of the trials that Jasmohan Bajaj, MD is conducting.
What is the office address of Jasmohan Bajaj, MD?
The office of Jasmohan Bajaj, MD is located at: Hunter Holmes McGuire VA Medical Center, Richmond, Virginia 23249 United States. This is the address for their practice at the Hunter Holmes McGuire VA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.